NovoCure Limited (NASDAQ:NVCR) Receives Average Rating of “Hold” from Brokerages

NovoCure Limited (NASDAQ:NVCR) has been given an average rating of “Hold” by the seven brokerages that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $26.9286.

A number of research analysts have recently weighed in on NVCR shares. Weiss Ratings reissued a “sell (e+)” rating on shares of NovoCure in a research report on Thursday, January 22nd. Wedbush reiterated a “neutral” rating and issued a $18.00 price objective on shares of NovoCure in a research note on Thursday, January 15th. Evercore set a $20.00 target price on NovoCure in a research report on Monday, January 5th. Finally, HC Wainwright boosted their target price on NovoCure from $47.00 to $49.00 and gave the company a “buy” rating in a research note on Thursday, February 26th.

Insiders Place Their Bets

In other NovoCure news, Chairman William F. Doyle sold 71,887 shares of the company’s stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $12.98, for a total transaction of $933,093.26. Following the sale, the chairman directly owned 328,397 shares of the company’s stock, valued at $4,262,593.06. This represents a 17.96% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, COO Mukund Paravasthu sold 43,246 shares of the stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $13.77, for a total transaction of $595,497.42. Following the transaction, the chief operating officer owned 72,832 shares of the company’s stock, valued at $1,002,896.64. This represents a 37.26% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 140,041 shares of company stock worth $1,860,116 in the last ninety days. 5.52% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. raised its holdings in NovoCure by 4.8% during the 4th quarter. Vanguard Group Inc. now owns 10,958,209 shares of the medical equipment provider’s stock valued at $141,690,000 after acquiring an additional 502,368 shares during the period. Soleus Capital Management L.P. grew its position in shares of NovoCure by 25.0% in the second quarter. Soleus Capital Management L.P. now owns 6,904,302 shares of the medical equipment provider’s stock valued at $122,897,000 after purchasing an additional 1,382,888 shares in the last quarter. Morgan Stanley raised its stake in shares of NovoCure by 453.4% during the 4th quarter. Morgan Stanley now owns 5,069,895 shares of the medical equipment provider’s stock valued at $65,554,000 after purchasing an additional 4,153,741 shares during the period. Balyasny Asset Management L.P. lifted its holdings in NovoCure by 38.8% during the 2nd quarter. Balyasny Asset Management L.P. now owns 2,270,076 shares of the medical equipment provider’s stock worth $40,407,000 after purchasing an additional 634,925 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its stake in NovoCure by 29.4% in the 4th quarter. Renaissance Technologies LLC now owns 1,387,754 shares of the medical equipment provider’s stock worth $17,944,000 after purchasing an additional 314,900 shares during the period. 84.61% of the stock is owned by institutional investors.

NovoCure Trading Up 6.0%

Shares of NovoCure stock opened at $14.23 on Friday. The firm has a market cap of $1.62 billion, a PE ratio of -11.66 and a beta of 0.71. NovoCure has a 1 year low of $9.82 and a 1 year high of $21.55. The company has a debt-to-equity ratio of 0.70, a current ratio of 2.90 and a quick ratio of 1.50. The stock has a fifty day moving average price of $12.75 and a 200-day moving average price of $12.71.

NovoCure (NASDAQ:NVCR) last posted its quarterly earnings results on Thursday, February 26th. The medical equipment provider reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.41) by $0.19. NovoCure had a negative net margin of 20.79% and a negative return on equity of 39.11%. The company had revenue of $174.35 million during the quarter, compared to analyst estimates of $174.40 million. During the same quarter in the prior year, the business earned ($0.61) earnings per share. The firm’s revenue for the quarter was up 8.2% on a year-over-year basis. Equities research analysts anticipate that NovoCure will post -1.3 EPS for the current year.

Key NovoCure News

Here are the key news stories impacting NovoCure this week:

• Negative Sentiment: Chairman William F. Doyle sold 71,887 shares at an average price of $12.98 (~$933,093). He reduced his stake by 17.96%. SEC Filing
• Negative Sentiment: COO Mukund Paravasthu sold 43,246 shares at an average of $13.77 (≈$595,497), a 37.26% reduction in his holdings. SEC Filing
• Negative Sentiment: COO Mukund Paravasthu also sold 5,377 shares at an average of $13.31 (~$71,568) in a separate filing. SEC Filing
• Negative Sentiment: CEO Frank X. Leonard sold 5,607 shares at $13.31 (~$74,629), a 1.12% reduction in his stake. SEC Filing
• Negative Sentiment: CFO Christoph Brackmann sold 6,412 shares at $13.31 (~$85,344), a 3.39% reduction. SEC Filing
• Negative Sentiment: Insider Uri Weinberg sold 6,412 shares at $13.31 (~$85,344), a 2.34% decrease in holdings. SEC Filing
• Negative Sentiment: Insider Michal Nath Puri sold 1,100 shares at $13.31 (~$14,641), a 0.54% reduction. SEC Filing

About NovoCure

NovoCure is a global oncology company pioneering Tumor Treating Fields (TTFields), a novel anti-mitotic therapy for solid tumors. The company’s non-invasive treatment platforms deliver low-intensity, alternating electric fields designed to disrupt cancer cell division. NovoCure’s approach offers an alternative modality to complement existing therapies in oncology, with a focus on hard-to-treat malignancies.

Founded in 2000 and headquartered in Haifa, Israel, NovoCure maintains a second operational center in Portsmouth, New Hampshire.